Encysive gets European marketing approval for hypertension drug

By Elaine Rigoli

Tampa, Fla., Aug. 10 - Encysive Pharmaceuticals Inc. said the European Commission has granted marketing authorization for hypertension drug Thelin (sitaxentan sodium) in the European Union.

The company said it is awaiting the formal decision letter from the European Commission.

Encysive is a biopharmaceutical company located in Houston.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.